When Pills Fail: Psychotherapy for Treatment-Resistant Depression Finally Gets Its Meta-Analysis
- First meta-analysis dedicated to psychotherapy for treatment-resistant depression (TRD) in adults — pooled analysis shows a small-to-moderate but significant effect on depressive symptoms vs. control
- Psychotherapy works for TRD even when added to ongoing pharmacotherapy — the combination outperforms medication alone
- CBT is the most studied modality for TRD, but behavioral activation, CBASP, and mindfulness-based approaches also show promise
- Effect sizes are smaller than for non-resistant depression — expected, but confirms that TRD is not untreatable with psychological intervention
Treatment-resistant depression — defined as failure to respond to at least two adequate antidepressant trials — affects roughly 30% of people with major depression. For decades, the response was pharmacological escalation: switch, augment, combine. Psychotherapy for TRD was an afterthought, recommended in guidelines but with the evidence base of an orphan. This 2025 meta-analysis changes that. Not dramatically — the effects are modest — but definitively: psychological therapy works for TRD, and the evidence is now pooled and quantified.
What the data shows
The pooled effect is small-to-moderate, which is exactly what you would predict for a population defined by treatment failure. These patients have already not responded to first-line interventions. Any significant effect in this group represents clinical progress that purely pharmacological approaches could not achieve alone.
CBT dominates the evidence base, but not exclusively. Behavioral activation — simpler, more scalable, and deliverable by non-specialists — shows effects. CBASP (Cognitive Behavioral Analysis System of Psychotherapy), designed specifically for chronic depression, appears in the included trials. Mindfulness-based cognitive therapy (MBCT) also contributes, consistent with NICE guidelines recommending it for recurrent depression.
The combination is the message
The clearest finding: psychotherapy added to ongoing pharmacotherapy outperforms pharmacotherapy alone. This is not a contest between pills and therapy. It is evidence that for patients who have not responded to medication, adding structured psychological intervention produces incremental benefit. The practical implication: the referral for therapy should not wait until all medication options are exhausted. It should happen at the point of treatment resistance.
For your practice
If you treat depression and have patients who are not responding to medication: the evidence now supports adding psychotherapy at the point of treatment resistance, not as a last resort. For therapists receiving TRD referrals: set expectations appropriately — effect sizes are smaller than for first-episode depression. Progress may be slower. But it is real, measurable, and clinically meaningful. Consider CBT or behavioral activation as first choices; CBASP for chronic presentations; MBCT for recurrent patterns.
Treatment-resistant depression is not therapy-resistant. The effect is modest, but for patients who have failed two medications, modest is meaningful.
Heterogeneous definitions of TRD across included studies. Small number of trials per specific modality. Control conditions varied (TAU, waitlist, active control). Longer-term follow-up data limited.